BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)

Trial Profile

BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Golimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms BioTRAC
  • Sponsors Janssen Inc; Merck & Co
  • Most Recent Events

    • 23 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 08 Nov 2017 Results (n=629) assessing the impact of disease duration on clinical and patient-reported outcomes in patients with psoriatic arthritis or ankylosing spondylitis treated with subcutaneous golimumab presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 08 Nov 2017 Results (n=63) assessing the safety and effectiveness of Ustekinumab in patients with Psoriatic Arthritis over a 6 month period, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top